FYI. Not oncology.
But Semaglutide was #5 in line for GLP1 agonists available to the public. I don't think anyone will argue that this isn't the most successful GLP1 agonist. Launched 12 years after Exenatide.
Being 1st in class can have advantages. But there's a lot more to it.
Same class does not correlate to best in class. Or best marketing for that matter.
As a dietitian, I assume you would've known that.
There are a lot of BP companies competing for market share out there. As there are patients with cancer.
Plenty of room for multiple players.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $179.4K | 14.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 15731879 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3463196 | 20 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |